Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

Journal of Clinical Oncology

Volumn 14, Issue 5, 1996, Pages 1552-1557

  Kudelka, A P ^a   Tresukosol, D ^a   Edwards, C L ^a   Freedman, R S ^a   Levenback, C ^a   Chantarawiroj, P ^a   Gonzalez de Leon, C ^a   Kim, E E ^a   Madden, T ^a   Wallin, B ^a   Hord, M ^a   Verschraegen, C ^a   Raber, M ^a   Kavanagh, J J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOPOTECAN;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; OVARY CARCINOMA; PRIORITY JOURNAL; RASH;

EID: 9244247616     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.5.1552     Document Type: Article

References (20)

1. Omura GA, Brady MF, Homesley HD, et al: Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience. J Clin Oncol 9:1138-1150, 1991
2. Alberts DS, Green S, Hannigan EV, et al: Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stage III and IV ovarian cancer. J Clin Oncol 10:706-717, 1992
3. Markman M, Rothman R, Hakes T, et al: Second-line platinum therapy in patients with ovarian cancer previously treated with cis-platin. J Clin Oncol 9:389-393, 1991
4. Kohn EC, Sarosy G, Bicher A, et al: Dose-intense Taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 86:18-24, 1994
5. Rowinsky EK, Grochow LB, Hendricks CB, et al: Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibiter. J Clin Oncol 10:647-656, 1992
6. Liu LF: DNA topoisomerase poisons as antitumor drugs. Ann Rev Biochem 58:351, 1989
7. Slichenmyer WJ, Rowinsky EK, Donehower RC, et al: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85:271-291, 1993
8. Kudelka AP, Edwards C, Freedman R, et al: An open phase II study to evaluate the efficacy and toxicity of topotecan administered intravenously as 5 daily infusions every 21 days to women with advanced epithelial ovarian carcinoma. Proc Am Soc Clin Oncol 12:259, 1993 (abstr 821)
9. Markman M: Response to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population. J Clin Oncol 10:513-514, 1992
10. Grochow LB, Rowinsky EK, Johnson R, et al: Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos 20:706-713, 1992
11. Mattern MR, Mong SM, Bartus HF, et al: Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in culture L1210 cells. Cancer Res 47:1793-1798, 1987
12. Horwitz SB, Horwitz MS. Effects of camptothecin on the breakage and repair of DNA during cell cycle. Cancer Res 33:2834-2836, 1973
13. Pommier Y: Topoisomerase inhibitors: Why do they work? Why do they fail? Proc Am Soc Clin Oncol 34:567, 1993 (abstr)
14. Seymour MT, Mansi JL, Gallagher CJ, et al: Protracted oral etoposide in epithelial ovarian cancer: A phase II study in patients with relapsed or platinum-resistant ovarian disease. BMJ 69:191-195, 1994
15. Moore DH, Valea F, Crumpler LS, et al: Hexamethlmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma. Gynecol Oncol 51:109-112, 1993
16. Markman M, Hakes T, Reichman B, et al: Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease. J Clin Oncol 10:243-248, 1992
17. Swenerton K, Eisenhauer E, ten Bokkel Huinink W, et al: Taxol in relapsed ovarian cancer: High vs low dose and short vs long infusion: A European-Canadian study coordinated by the NCI Canada Clinical Trials Group. Proc Am Soc Clin Oncol 12:256, 1993 (abstr 810)
18. Markman M, Hakes T, Reichman B, et al: Memorial Sloan-Kettering Cancer Center experience with National Cancer Institute Treatment Referral Center Protocol 9103: Taxol in refractory ovarian cancer. Proc Am Soc Clin Oncol 12:266, 1993 (abstr 851)
19. Holmes FA, Kudelka AP, Kavanagh JJ, et al: Current status of clinical trials with paclitaxel and docetaxel, in Georg GI, Chen TC, Ojima I, et al (eds): ACS Symposium-in-Print. Taxane Anticancer Agent: Basic Science and Current Status, vol 3, 1994, pp 31-57
20. Miller AA, Hargis JB, Fields S, et al: Phase I study of topotecan and cisplatin in patients with advanced cancer. Proc Am Soc Clin Oncol 12:399, 1993 (abstr 1367)